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Background: The G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) is a common cause of cystic fibrosis (CF).
G551D-CFTR is characterized by an extremely low open probability despite its normal trafficking to the plasmamembrane. Numerous small molecules
have been shown to increase the activity of G551D-CFTR presumably by binding to the CFTR protein.
Methods: We investigated the effect of curcumin, genistein and their combined application on G551D-CFTR activity using the patch clamp technique.
Results: Curcumin increased G551D-CFTR whole-cell and single-channel currents less than genistein did at their maximally effective
concentrations. However, curcumin further increased the channel activity of G551D-CFTR that had been already maximally potentiated by
genistein, up to ~50% of the WT-CFTR level. In addition, the combined application of genistein and curcumin over a lower concentration range
synergistically rescued the gating defect of G551D-CFTR.
Conclusions: The additive effects between curcumin and genistein not only support the hypothesis that multiple mechanisms are involved in the
action of CFTR potentiators, but also pose pharmaceutical implications in the development of drugs for CF pharmacotherapy.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; CFTR; G551D mutation; Genistein; Curcumin; Additive effect1. Introduction
The cystic fibrosis transmembrane conductance regulator
(CFTR) chloride channel is a major player in salt and water
transport across epithelia and mutations of CFTR that cause the
reduction of its activity result in the genetic disease cystic fibrosis
(CF) [18,38]. Cystic fibrosis is characterized by the absence of a
cAMP-stimulated Cl− current across a variety of epithelia⁎ Corresponding author at: Department of Pharmacology and Neuroscience, Keio
Japan. Tel.: +81 3 5363 3750; fax: +81 3 3359 8889.
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doi:10.1016/j.jcf.2011.03.001including the nasal epithelium [27], airway epithelia [46],
pancreatic ducts [20], sweat glands [37], and the intestine [38].
There are different mechanisms that cause CFTR channel
dysfunction [47], and different pharmacological approaches are
currently being explored to alleviate the disease [5]. Many
compounds, so called CFTR potentiators, have been found to
boost the activity of mutant CFTR channels with low open
probability, but few of them seem to be able to completely rescueUniversity School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582,
d by Elsevier B.V. All rights reserved.
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et al. [41] have recently shown that 1 μM VX-770 restored the
open probability of ΔF508-CFTR to that of wild-type CFTR.
The glycine-to-aspartate missense mutation at position 551
(G551D) is the third most common CF-associated mutation, with
a worldwide frequency of 3.1% (www.genet.sickkids.on.ca/cftr).
The G551D-CFTR protein is a class III mutation [47]. This
mutant CFTR protein can traffic normally to the apical membrane
and is phosphorylated by cAMP-dependent protein kinase A
(PKA) [12,14,30,47] but it exhibits defective gating [9,11,30,47].
Among the many compounds that potentiate G551D-CFTR
currents, genistein is perhaps the most extensively studied.
Genistein is a bioflavonoid found in legumes [16] and has been
known as a CFTR potentiator for more than a decade [6,21,23].
Interestingly, it has also been demonstrated that genistein has
inhibitory actions at high concentrations [28,39,43]. Although the
exact mechanism of action for genistein remains elusive, studies
have identified putative binding sites for genistein on CFTR [33],
while other studies have suggested that the drug acts by altering
lipid bilayer mechanics [22].
Curcumin is a component of the spice turmeric and is known
for its antioxidant, anti-inflammatory, wound-healing, anti-
carcinogenic, antiviral, anti-infectious, anti-amyloidogenic and
anti-cancer effects [2,19,26,32,35]. Egan et al. [17] reported that
oral administration of curcumin to ΔF508-CFTR mice could
correct the trafficking defects of mutant CFTR, although these
results remain controversial [e.g., 40]. Interestingly, Berger et al.
[7] showed that curcumin potentiatedWT- andΔF508-CFTR and
Wang et al. [44] reported that curcumin strongly activated mutant
CFTR channelswith very low activities, includingG551D-CFTR.
In this study, we investigated the effects of genistein, curcumin
and their combined application on the G551D-CFTR gating
defects.
2. Materials and methods
2.1. Cells, cell culture, DNA constructs and transfection
CHO cells were grown at 37 °C and 5% CO2 in Dulbecco's
modified Eagle's medium supplemented with 10% FBS.
To transiently express CFTR, CHO cells were grown for 1 day
in 35-mm tissue culture dishes at an initial seeding density of
0.5–1×105 cells/ml. The DNA constructs, encoding WT or
G551D-mutant CFTR, were separately cotransfected with
~0.2 μg of pEGFP-C3 (CLONTECH Laboratories Inc., Moun-
tain View, CA, USA) encoding GFP, using SuperFect transfec-
tion reagent (QIAGEN, Hilden, Germany) according to the
manufacturer's protocols. After transfection for 2–6 days, the
transfected cells were detached using 0.05% trypsin in phosphate-
buffered saline (PBS) (0.25% trypsin/1 mM EDTA diluted with
PBS, Sigma-Aldrich, St. Louis, MO, USA), and kept as a cell
suspension before use.
2.2. Electrophysiological recording and analysis
All CFTR currents were recorded at room temperature with an
EPC9 amplifier (HEKA, Lamberecht/Pfalz. Germany) or anAxopatch 200A patch clamp amplifier (Axon Instruments, Inc,
Foster City, CA, USA).
2.2.1. Whole-cell recordings
The pipette resistance was ~5 MΩ in the bath solution. To
monitor the effect of drugs on CFTR currents, the membrane
potential was held at 0 mV and a 1 s voltage ramp (−100 mV to
100 mV) was applied every 6 s. Currents were filtered at 1 kHz
with a built-in 4-pole Bessel filter, and digitized by the computer
at a sampling rate of 2 kHz. CFTR was activated with 10 μM
forskolin and 100 μM CPT-cAMP before the application of
curcumin or genistein. The net current was calculated as the
current between −100 mV and +100 mVminus the basal current
(leak current) at the same voltages, using Igor software
(Wavemetrics, Lake Oswego, OR) or Clampfit software
(Axon). Current–Voltage (I–V) relationships were obtained
when whole-cell currents reached a steady state under each
condition (Figs. 1AB and 3B). The bath solution contained
145 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 5 mM
glucose, and 5 mMHEPES (pH 7.4 with NaOH). 20 mM sucrose
was added to the bath solution to prevent activation of swelling-
induced currents. The pipette solution contained 10 mM EGTA,
10 mMHEPES, 20 mM TEACl, 10 mMMgATP, 2 mMMgCl2,
101 mM CsCl, and 5.8 mM glucose.
2.2.2. Cell-attached recordings
The pipette resistance was 3 to 5 MΩ in the bath solution. The
pipette potential (Vp) was held at +50 mV for all experiments.
Data were filtered at 100 Hz with an eight-pole Bessel filter
(Warner Instrument, Hamden, CT, USA) and digitized by the
computer at a sampling rate of 500 Hz. The NPo value was
estimated from the equation; NPo=I / i, where n is the number of
channels, I is the mean steady-state current and i is the unitary
current, using Igor software. The duration of the current
recordings used for the NPo analysis was longer than 60 s. The
pipette solution contained 140 mM N-methyl-D-glucamine chlo-
ride (NMDG-Cl), 2 mMMgCl2, 5 mMCaCl2, and 5 mMHEPES
(pH 7.4 with NMDG). The bath solution was the same as used for
whole-cell experiments.
2.3. Western blot analysis
Western blot analysis was performed forty-eight hours after
transfection, when cells were ~70% confluent on 35-mm dishes.
To prepare cell lysates, dishes were washed once with PBS, and
then lysis buffer was added (M-PER Protein Extraction reagent,
Thermo Scientific, Rockford, IL, USA). DNA was sheared by
brief sonication (~3 s). The whole cell lysates were separated on
7.5% Tris–HCl SDS-PAGE gels (Bio-Rad Laboratories Inc.,
Hercules, CA, USA) and transferred onto a nitrocellulose
membrane. The membrane was blocked with 5% milk in a Tris-
buffered saline with Tween (TBST) buffer (20 mMTris, 137 mM
NaCl, 0.05%Tween) at room temperature for 1 h and then probed
with a primary antibody against CFTR (clone CFTR#569 mAb, a
kind gift from Dr. J. R. Riordan) in PBS at 4 °C overnight. The
nitrocellulose membrane was washed with TBST three times and
then incubated with the horseradish peroxidase (HRP)-
Fig. 1. Potentiation effects of genistein and curcumin on whole-cell currents of G551D-CFTR channels expressed in CHO cells. (A) Effect of curcumin on G551D-CFTR
whole-cell currents stimulated by 10 μM FSK+100 μMCPT-cAMP. Representative traces for G551D-CFTR whole-cell currents affected by 30 μM curcumin. The right
panel shows the I–V relationships in control (at II) and curcumin (at III) after the subtraction of the leak-currents in the pulse at the position I. Representative of twelve data.
(B) Effect of genistein on G551D-CFTRwhole-cell currents stimulated by 10 μMFSK+100 μMCPT-cAMP. Representative traces for G551D-CFTRwhole-cell currents
affected by 80 μM genistein. The right panel shows the net I–V relationships in control (II–I) and genistein (III–I). Representative of eleven data. (C) The dose response
relationship for genistein (●) (n=11) and curcumin (■) (n=12). Error bars represent SEM. The fold-increase in the whole cell current (IWC) was calculated by dividing the
mean current at 100 mV in the presence of genistein or curcumin by the mean current in control after the leak current subtraction.
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Jackson ImmunoResearch Laboratories, West Grove, PA, USA)
for 1 h at room temperature. The membrane was developed with
chemiluminescence HRP substrate reagent (Millipore Corp.,
Billerica, MA, USA) for 5 min and exposed to ImageQuant LAS
4000 mini machine (GE Healthcare Bio-Science Corp., Uppsala,
Sweden). The membrane was cut in the region around 37 kDa
position, and reprobedwith an anti-actin antibody (sc-1616, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) and then
incubated with the HRP-conjugated secondary antibody (goat
anti-rabbit IgG; Sigma-Aldrich) for 1 h at room temperature for an
internal control of protein loading. For a quantitative comparison
of the expression level between WT- and G551D-CFTR, arelative intensity (CFTR/actin) was calculated by dividing the
signal intensity of CFTR protein by the signal intensity of actin in
each lane.
2.4. Reagents
Forskolin (FSK) was purchased from Alexis (San Diego, CA,
USA) and stored as a 20 mM stock in dimethyl sulfoxide
(DMSO) at −20 °C. 8-(4-chlorophenylthio) (CPT)-cAMP was
purchased from BioLog (Bremen, Germany) and stored as a
50 mM stock in water at −20 °C. Genistein was purchased from
Alexis and stored as a 100 mM stock in DMSO at −20 °C.
Curcumin was purchased from Sigma-Aldrich (St Louis, MO,
246 Y.-C. Yu et al. / Journal of Cystic Fibrosis 10 (2011) 243–252USA), stored as a 30 mM stock in DMSO at −20 °C and
dissolved in the bath solution just before use.
2.5. Statistics
All of the results are expressed as means±SEM. To compare
data, ANOVA and paired or non-paired t-test were performed
using SPSS (IBM Corp., Armonk, NY, USA) and Igor or Excel
(Microsoft, Redmond, WA, USA). Pb0.05 was considered
statistically significant.
3. Results
3.1. Effects of curcumin and genistein on G551D-CFTR
We first examined the effects of curcumin on G551D-CFTR
whole-cell current at different concentrations and compared
them with those of genistein. G551D-CFTR currents were
activated with 10 μM forskolin (FSK) and 100 μM CPT-cAMP
before the application of curcumin or genistein. Fig. 1A and B
are representative whole cell current traces which illustrate the
potentiating effects of 30 μM curcumin and 80 μM genistein on
G551D-CFTR whole-cell currents, respectively. Note that upon
removal of 80 μM genistein, we often observed a transient
current increase which might be caused by the release of the
inhibitory effect of genistein prior to the recovery of its
potentiation effect (data not shown). The I–V relationships were
slightly outwardly rectifying before and after the application of
the potentiators, with no change in the reversal potential.
Fig. 1C shows the dose response relationships for the fold-
increase caused by curcumin and genistein. Although it appears
that curcumin has a higher apparent affinity than genistein, the
maximum fold-increase for curcumin is significantly smaller
(10.2±2.2, n=12) than that for genistein (23.0±4.1, n=11).
This result indicates that genistein is a more effective potentiator
of G551D-CFTR than curcumin. Although the dose–response
relationship for curcumin follows a simple saturation function
up to 60 μM, the highest soluble concentration (Fig. 1C), a bell-
shape dose–response relationship is seen for genistein
(Fig. 1C), indicating an inhibitory effect of genistein at high
concentrations [31,33], similar to the effect observed for WT
channels [28,33,39,43].
To examine the potentiation of CFTR by both compounds
further, we tested their effects on G551D-CFTR in the cell-
attached mode that had been activated first by forskolin and
cAMP. Fig. 2A andB shows representative single channel current
traces before and after exposure to genistein and curcumin,
respectively. 80 μMgenistein significantly increased the G551D-
CFTR channel activity in the cell-attached patch in a reversible
manner (Fig. 2A). This effect was apparently due to an increase of
the channel burst time and a decrease of the closed time as
reported previously [25]. In contrast, 30 μM curcumin only
slightly increased the G551D-CFTR channel activity in the cell-
attached patch (Fig. 2B). The application of genistein or curcumin
also changed the single channel current amplitudes (see Fig. 2B
legend). This effect on channel amplitude might be caused by
changes in the membrane potential and/or the intracellular Cl−concentration, induced by opening of G551D-CFTR channels in
the entire cell membrane, in addition to a pore blocking effect
which has been previously reported for genistein [28].
Fig. 2C summarizes the fold-increase of NPo induced by
curcumin and by genistein. Although, compared to data generated
from whole-cell experiments, the potentiation effects of genistein
or curcumin are dramatically reduced, at the tested concentrations,
genistein remains a more effective potentiator than curcumin.
3.2. Additive effects of genistein and curcumin
There are at least two possibilities to explain the results shown
above. First, these two potentiators may act through a similar
mechanism, but, compared to genistein, curcumin serves as a
partial agonist. This scenario is very similar to the one proposed
for capsaicin [3]. Second, curcumin and genisteinmay act through
two completely different mechanisms. These two ideas can be
differentiated by adding curcumin and genistein together. The
first proposition entails a partial inhibition by curcumin applied
after CFTR currents are maximally activated by genistein. On the
other hand, an additive effect between curcumin and genistein
would suggest two different mechanisms of action.
In the whole-cell recording mode, after activating the G551D-
CFTR channels by 10 μMFSK and 100 μMCPT-cAMP, we first
applied 80 μM genistein which is the maximally effective
concentration. Once the whole-cell current reached steady state,
30 μM curcumin was added in the continued presence of
genistein (Fig. 3A). The additional application of 30 μM
curcumin produced a further increase in the G551D-CFTR
whole-cell current already potentiated by 80 μM genistein
(Fig. 3AB). A similar additive effect was observed when
G551D-CFTR currents were initially activated by 30 μM
curcumin and subsequently exposed to 80 μM genistein (data
not shown). Fig. 3C summarizes the fold-increase of G551D-
CFTR whole cell currents induced by various combinations of
different concentrations of genistein and curcumin. This additive
effect suggests that curcumin and genistein can potentiate CFTR
channel activity through different mechanisms. It is also worth
noting that a combination of relatively low concentrations of
genistein and curcumin showed a significant fold-increase in
G551D-CFTR currents (Fig. 3C). For example the combined
application of 10 μM genistein and 5 μM curcumin produced a
very large synergistic effect (~30 fold) that increased the G551D
whole-cell currents to levels obtained with much higher doses of
the two compounds (Fig. 3C). This also contrasts markedly with
the much smaller ~2–3 fold potentiation observed when 10 μM
genistein or 5 μM curcumin was applied alone (Fig. 1C).
To further confirm these whole-cell experimental results, we
carried out similar experiments in the cell-attached mode. Fig. 4A
shows representative single channel current data obtained from a
cell-attached patch containing G551D-CFTR. 80 μM genistein
increased the channel activity of cAMP-stimulated G551D-CFTR
in the cell-attached patch. The additional application of 30 μM
curcumin further increased the genistein-potentiatedG551D-CFTR
channel activity (Fig. 4A). Fig. 4B shows the summary of the NPo
fold-increases induced by 80 μM genistein (5.6±0.8, n=10) and





























Fig. 2. Potentiation effects of genistein and curcumin on G551D-CFTR observed in cell-attached mode. Representative cell-attached single-channel recordings of cAMP-
stimulated G551D-CFTR channel currents potentiated by genistein (A) and curcumin (B). The G551D-CFTR channels are continuously stimulated by 10 μM FSK and
100 μMCPT-cAMP.Vp=+50 mV. Single channel amplitude: (A) control: 0.26 pA, genistein: 0.26 pA, wash out: 0.22 pA, (B) control: 0.41 pA, curcumin: 0.31 pA, wash
out: 0.53 pA. (C) Summary of fold-increase of NPo induced by 80 μMgenistein (n=5) and 30 μMcurcumin (n=5). G551D-CFTRwas expressed in CHO cells. Error bars
represent SEM. Non-paired t-test, **: Pb0.01.
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potentiate CFTR channel activity through different mechanisms.
3.3. Estimation of the restoration of G551D gating defect by
genistein and curcumin
Finally we attempted to quantify how much the combined
application of genistein/curcumin restored the G551D gating
defect, in comparison to WT-CFTR.
Fig. 5A summarizes the current densities of the G551D-CFTR
whole-cell currents obtained after exposure to various combina-
tions of different concentrations of curcumin and genistein. It is
clear from the data that for each combination of genistein and
curcumin there was a clear and statistically significant potenti-
ation in G551D-CFTR current density, which reached levels that
were approximately half of the WT-CFTR level, however, therewas no statistical difference between the data sets (Fig. 5A)
because of the large variation in the absolute whole-cell CFTR
current density probably caused by heterogeneous CFTR
expressions in the transient expression system.
Fig. 5B shows a comparison of Western blots obtained
fromCHO cells expressingWT- andG551D-CFTR proteins. The
CFTR proteins were separated into two bands: one for fully
glycosylated mature proteins (band C) and another for non-
glycosylated immature proteins (band B) (Fig. 5B-a). The nor-
malized band C signal intensities suggested that the expres-
sion level of G551D-CFTR is approximately 2-fold higher than
that of WT-CFTR in our transient expression system (Fig. 5B-b),
although it should be noted that the Western blot is poorly
quantitative.
Based on these data, we speculate that the combined
application of curcumin and genistein can compensate for up to
Fig. 3. Additive effect of curcumin and genistein on G551D-CFTR whole-cell
currents. (A) Representative whole-cell current trace from G551D-CFTR
expressed in CHO cells, showing the additive effect of curcumin and genistein.
Representative of eleven data. (B) The I–V relationships of the net G551D-CFTR
whole-cell currents. The net whole-cell currents were obtained by subtracting the
(leak) whole-cell currents at I from the whole-cell currents at II (control), III
(genistein) and IV (genistein+curcumin) in Fig. 3A. (C) Comparison of fold-
increases in the G551D-CFTR whole-cell currents (IWC) in control, induced by
10–80 μM genistein alone and additional applications of 5–30 μM curcumin to
different genistein concentrations. Error bars represent SEM.ANOVA, *: Pb0.05;
**: Pb0.01.
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WT-CFTR level.
4. Discussion
In this study, we investigated the potentiation effects of
curcumin, genistein and their combined applications on G551D-
CFTR and found that the combined application of these two
reagents can cause additive effects, which suggests that the two
compounds might work through different mechanisms.
4.1. Genistein and curcumin
There are different mechanisms that cause CFTR channel
dysfunction [47], but when the defective proteins are present in
the apical membrane, pharmacological agents that increase theactivity of the mutant channels are of potential clinical value in
the treatment of CF. Compounds that increase CFTR activity
include isoflavones (e.g. genistein [24,48]), flavones (e.g.
apigenin [24]), capsaicin [3], phenylglycines (e.g. PG-01 [36]),
sulfonamides (e.g. SF-01 [36]), 1,4-dihydropyridines [36],
benzoflavones (e.g. UCCF-029 [10]), benzimidazolones (e.g.
NS004 [4] and UCCF-853 [10]), pyrrolo[2,3-b]pyrazines deri-
vatives (e.g., RP107 [34]), benzo[c]quinolizinium derivatives
(e.g., MPB-91 [15]) and curcumin [7,8]. Although the detailed
mechanism through which these compounds increase CFTR
activity is still unclear, some potentiators seem to share a common
mechanism of action or binding site since no additive effect is
observed when applied together, as shown for genistein and
NS004 [4], genistein and UCCF-029 [10] or genistein and
capsaicin [3]. On the other hand, UCCF-029 andUCCF-853 seem
to work through different binding sites, since they exhibited an
additive effect when applied together [10].
Of all the potentiators genistein is perhaps the most studied.
Since genistein increases CFTR currents in excised patches, it has
been proposed that genistein's target is the CFTR molecule itself
[43,45]. This reagent clearly affects the ATP-dependent gating of
CFTR channels, increasing the opening rate and decreasing the
closing rate, consistent with what one would expect if the drug
acts at the NBD dimer [3,17,28,29,32]. Wang et al. [43] reported
that the dose response of genistein for WT channels exhibited a
bell shape with the maximum potentiation effect at about 40 μM.
In this study, we found that the genistein dose response for
G551D-CFTR channels also showed a bell-shape, although the
maximally effective concentration was shifted towards higher
[genistein] at around 80 μM. This shift is in agreement with
previous results [33]. Although it was reported that the amino acid
at position 551 is part of the potentiator binding site [33], this may
not be the only interpretation for the shift in the genistein dose
response. The dose response measurement of the potentiator-
induced CFTR current enhancement is just a functional assay in
which the ligand binding process itself is not directlymeasured. A
decrease of the Po by the G551D mutation can produce a shift of
the dose response curve simply because there is more room for an
activity increase in G551D-CFTR versus the wild-type channels.
Alternatively, if binding of the potentiator alters gating, then
gating will have to alter binding based on thermodynamic
principles [13]. Also the pore blocking effect of genistein [28]
might affect the dose–response of G551D-CFTR whole cell
currents (e.g., Fig. 1C), but its contribution is likely to be small.
Thus, one has to exert great caution in interpreting concentration/
effect relationships.
Wang et al. [44] reported that curcumin opened CFTR
channels, including G551D-CFTR, by a novel mechanism that
required neither ATP nor NBD2 whereas it was strongly
dependent on prior phosphorylation by PKA. Moreover a
biochemical study [8] showed that curcumin cross-linked a
wide variety of CFTR constructs including G551D-CFTR at
similar concentrations and durations of exposure employed in this
study. However, it is unlikely that such cross-linking itself had a
significant influence on the CFTR channel function [8]. Actually
it was reported that one cyclic derivative of curcumin, that had no


























Fig. 4. Additive effect of curcumin and genistein on G551D-CFTR in cell-attached mode. (A) Representative traces for the additive effect of curcumin and genistein on
G551D-CFTR single channel currents in cell-attachedmode. TheG551D-CFTR channels, expressed in CHO cells, are continuously stimulated by 10 μMFSK and 100 μM
CPT-cAMP. Vp=+50 mV. Single channel amplitude: control: 0.27 pA, genistein: 0.35 pA, genistein+curcumin: 0.30 pA, wash out: 0.31 pA. (B) Comparisons of relative
fold-increase inNPo ofG551D-CFTR single channel induced by 80 μMgenistein alone and a combined application of 80 μMgenistein and 30 μMcurcumin (n=10). Error
bars represent SEM. Paired t-test, **: Pb0.01.
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curcumin-induced potentiation is still unclear.4.2. The additive effect of genistein and curcumin
In this present study, we confirm that curcumin potentiates
G551D-CFTR reversibly within our experimental time frame,
whereas the effect of curcumin is quantitatively smaller than that
of genistein up to the highest soluble concentration, 60 μM. A
biphasic dose–response relationship for genistein was observed,
but there was no evidence for an inhibitory effect of curcumin
over the range of concentrations tested. Importantly, genistein and
curcumin additively potentiate G551D-CFTR channels, that is,
G551D-CFTR channel activity maximally potentiated by genis-
tein was further increased by curcumin (Figs. 3, 4 and 5). These
observations are consistent with the conclusion that genistein and
curcumin affect G551D-CFTR through different mechanisms.
However, Berger et al [7] demonstrated that addition of increasing
concentrations of curcumin in the presence of genistein inhibited
wild-typeCFTRCl- currents.While further studies are required tounderstand the synergistic effects of genistein and curcumin on
G551D-CFTR, our results highlight the potential benefit of
combinations of different CFTR potentiators, as they might result
in stronger effects being achieved at lower drug concentrations.
Although we made qualitatively similar observations in both
whole-cell and cell-attached recordings, there are significant
quantitative differences between the results obtained in the two
recording configurations. (compare Figs. 1C and 2C). The reason
for this discrepancy is unclear, and beyond the scope of this paper,
but one should note that many factors may affect the response of
mutant CFTR to potentiators, such as phosphorylation status of
the channel [28,43] and differences in the ATP levels present in
the cytosol of the two systems. Also the dialysis of the
cytoplasmic milieu for whole-cell recordings may also contribute
to these differences.4.3. Clinical implications
Our results also have important clinical implications for the
pharmaceutical therapy of CF because few of the known CFTR
Fig. 5. Summary of the effects of curcumin and genistein on G551D-CFTR whole-cell current density. (A) Current densities of G551D-CFTR expressed in CHO cells
obtained fromwhole cell currents potentiated by various combinations of curcumin and genistein are indicated. Note that the current density (whole-cell current normalized
by cell capacitance) data show some differences from the fold-increase data in Fig. 3C because of wide variation in current values. Error bars represent SEM. ANOVA,
*: Pb0.05; **: Pb0.01. (B) Western blot analysis for WT- and G551D-CFTR proteins expressed in CHO cells. (a) Representative of three western-blot data. Band B:
~150 kD; Band C: ~170 kD. (b) Comparison of the relative intensity (CFTR/actin) between WT- and G551D-CFTR proteins (band C) (n=3). Normalized to the relative
intensity of WT-CFTR. Non-paired t-test *: Pb0.05.
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restore the activity (Po) of mutants associated with severe CF [5].
This is of concern especially for mutants such as G551D-CFTR
which, despite trafficking normally to the membrane, exhibit very
low Po [9]. Recently Accurso et al. [1] reported that the CFTR
potentiator VX-770 rescued ~30–40% of the G551D gating
defect [41], andwas associatedwithwithin-subject improvements
in CFTR and lung function. Zegarra-Moran et al. [48] reported
that 200 μMgenistein rescued the gating defect of G551D-CFTR
of up to 20% of the WT-CFTR level. Importantly, our studies
have shown that the combined application of genistein and
curcumin in a lower concentration range showed a synergistic
effect of restoring the gating defect of G551D-CFTR of up
to ~50%of theWT-CFTR level (Figs. 3C and 5A). Thus, our data
suggest that even if each compound by itself cannot potentiate the
channel activity of theCFTRmutants to a level that is beneficial topatients with CF, a combination of the two compounds might
achieve a therapeutic level of correction, while minimizing
potential harmful side-effects by lowering each dose.
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